Unleashing the Power of AI: Eupnea's New Game-Changing Platform that Transforms Tuberculosis Management

Irvine, 15th May – Tuberculosis, a global health crisis affecting millions, is about to meet its match. According to the World Health Organization, tuberculosis is one of the top 10 causes of death globally, with over 1.6 million lives lost annually. The challenges faced by stakeholders in tuberculosis management, including awareness and access to good healthcare, expensive or inaccessible diagnosis, and adherence to long treatment timelines, necessitate innovative solutions that can revolutionize patient care. The urgency to find innovative solutions that streamline patient care and combat this persistent threat has never been greater.

Eupnea, a pioneering healthcare technology platform, is harnessing the transformative power of artificial intelligence to tackle the challenges of tuberculosis management head-on. Eupnea is creating awareness about the global tuberculosis crisis and introducing its innovative AI-based diagnosis and treatment platform as a solution. Eupnea's cutting-edge platform offers a revolutionary approach to address the challenges faced by patients, healthcare providers, and governments in managing tuberculosis effectively.

"We focused our attention on the three biggest pain points for the stakeholders: access to healthcare, expensive or inaccessible diagnostic tests, and adherence to treatment - and we set about fixing them all," said Lakshmi Narke, Founder at Eupnea. "At Eupnea, we envision a world where every person can access accurate and timely tuberculosis diagnosis, receive treatment, and regain control over their respiratory health."

The heart of Eupnea's innovation lies in its ability to accurately predict the risk range of tuberculosis through a unique cough analysis model. Analyzing just a 3-5 second audio clip of a cough, the platform rapidly identifies potential cases, enabling early detection and intervention.
Going beyond diagnosis, Eupnea's platform addresses the challenges of the tuberculosis skin test, a traditional hurdle in patient care. By providing guidance and eliminating the need for multiple doctor visits, the platform simplifies the diagnostic journey, ensuring convenience, accessibility, and greater patient compliance. By tracking the induration size using a simple coin placement method, patients can actively monitor their progress, taking charge of their own respiratory health.

A young patient depicting how he is using Eupnea’s gamified adherence plan.
However, Eupnea understands that effective treatment doesn't stop at diagnosis. Recognizing the critical issue of treatment adherence, the platform employs a gamified approach that engages and motivates patients like never before. Through an interactive system of badges and coupons, Eupnea fosters patient participation, leading to an anticipated improvement rate of 75%. By transforming the treatment journey into an empowering experience, Eupnea offers a lifeline for patients and a catalyst for better outcomes.

Furthermore, Eupnea's comprehensive doctor's dashboard offers valuable insights for healthcare providers. The dashboard tracks the patient's journey, enabling healthcare professionals to monitor progress, personalize care, and make informed decisions based on real-time data. With this holistic view, healthcare providers can optimize treatment plans and improve patient outcomes.

Dr. Maria Sanchez, a renowned tuberculosis specialist, and advocate, commends Eupnea's innovative approach to tuberculosis management. She states, "Eupnea's AI-based diagnosis and treatment platform represents a significant leap forward in the fight against tuberculosis. The integration of advanced artificial intelligence algorithms and gamified elements offers a promising solution to the challenges faced by both patients and healthcare providers."

Dr. Sanchez's endorsement underscores the transformative impact of Eupnea's platform and reinforces the urgent need for innovative solutions in tuberculosis management. With the support of medical experts like Dr. Sanchez, Eupnea's AI-powered platform is gaining recognition as a game-changer in the global battle against tuberculosis.

Eupnea invites the public to become aware of the global tuberculosis crisis and take proactive steps toward respiratory health. For more information about Eupnea and its transformative AI-based platform, please visit www.eupnea.com. Media inquiries and interview requests can be directed to Lakshmi Narke at lnarke@uci.edu
About Eupnea:
Eupnea is a leading healthcare technology platform focused on revolutionizing TB management. By harnessing the power of artificial intelligence, Eupnea develops innovative solutions to address critical public health challenges, such as tuberculosis. The company is committed to improving patient outcomes and revolutionizing healthcare delivery.

Contact:
Lakshmi Narke
lnarke@uci.edu

Chidroop I
ciyyhapp@uci.edu

Yogita Pattan
pattany@uci.edu